Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
8 pending office actions • 7 clients • 7 examiners • 6 art units • 0 of 8 (0%) have an AI response strategy ready
UltimatEdge IP Law Group, P.C. has managed 619 career applications, primarily within the Biotechnology & Pharmaceuticals technology area. The firm has a resolved allowance rate of 86.61 percent. This rate provides a benchmark for its historical success in securing patent grants within the life sciences sector.
On average, the firm experiences 2.81 office actions per allowance. This metric indicates that the prosecution process involves multiple rounds of negotiation with the patent office. There are currently 7 pending office actions requiring attention, which constitute the firm's immediate workload for active cases.
The combination of 619 career applications and an 86.61 percent allowance rate defines the firm's track record. Practitioners can use the 2.81 office actions per allowance to estimate the expected duration of future Biotechnology & Pharmaceuticals filings. These data points illustrate the firm's experience in its primary technical field.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §103 only | 3 (38%) |
| Double-patenting + other | 3 (38%) |
| Multi-statute (no §101) | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 2 | 55.4% | +46.2% |
| THOMPSON, CURTIS A | 1 | 60.8% | +52.7% |
| BOWERS, ERIN M | 1 | 54.7% | +10.6% |
| BREEN, KIMBERLY CATHERINE | 1 | 23.8% | +56.9% |
| HARTMANN, GARY S | 1 | 72.7% | +18.9% |
| FULTON, MICHAEL TIMOTHY | 1 | 70.4% | +5.9% |
| PETRITSCH, AMANDA MICHELLE | 1 | 57.1% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18392498 | Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration | BREEN, KIMBERLY CATHERINE | 29d overdue |
| 19385776 | Planar Motor Transport and System for Scalable, Multi-Purpose Lab Automation with Distributed Control Architecture and Temporal Reservation Management | THOMPSON, CURTIS A | — |
| 18487680 | Selectively Frictionally Engaged Hole Cover | HARTMANN, GARY S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18392498 | Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration | BREEN, KIMBERLY CATHERINE | 29d overdue |
| 18693468 | Reducing or Inhibiting Tissue Damage Using Hyaluronidase Administration | BOWERS, ERIN M | 3d overdue |
| 19385776 | Planar Motor Transport and System for Scalable, Multi-Purpose Lab Automation with Distributed Control Architecture and Temporal Reservation Management | THOMPSON, CURTIS A | — |
| 18978365 | Self-Retaining Implantable Drug Delivery Device | TCHERKASSKAYA, OLGA V | — |
| 18847245 | Compositions Having Improved Bioavailability of Therapeutics and Uses Thereof | TCHERKASSKAYA, OLGA V | — |
| 18487680 | Selectively Frictionally Engaged Hole Cover | HARTMANN, GARY S | — |
| 17596570 | Compositions, Kits, Methods and Uses for Preventing Microbial Growth | PETRITSCH, AMANDA MICHELLE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Med Progress, LLC | 2 |
| Lab Sync Inc. | 1 |
| Goldenbiotech, LLC | 1 |
| Trx Biosciences Limited | 1 |
| Clover Equipment | 1 |
| INFLOWVENT LTD. | 1 |
| Collidion | 1 |
| Art Unit | Apps |
|---|---|
| 1798 | 1 |
| 1653 | 1 |
| 1657 | 1 |
| 3671 | 1 |
| 1747 | 1 |
| 1612 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19385776 | Planar Motor Transport and System for Scalable, Multi-Purpose Lab Automation with Distributed Control Architecture and Temporal Reservation Management | Lab Sync Inc. | THOMPSON, CURTIS A | 1798 | §102§103§112 | Final Rejection | — | Pending | Nov 11, 2025 |
| 18978365 | Self-Retaining Implantable Drug Delivery Device | Goldenbiotech, LLC | TCHERKASSKAYA, OLGA V | §103DP | Non-Final OA | — | Pending | Dec 12, 2024 | |
| 18847245 | Compositions Having Improved Bioavailability of Therapeutics and Uses Thereof | Trx Biosciences Limited | TCHERKASSKAYA, OLGA V | §103§112DP | Non-Final OA | — | Pending | Sep 14, 2024 | |
| 18693468 | Reducing or Inhibiting Tissue Damage Using Hyaluronidase Administration | Med Progress, LLC | BOWERS, ERIN M | 1653 | §103DP | Final Rejection | 3d overdue | Pending | Mar 19, 2024 |
| 18392498 | Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration | Med Progress, LLC | BREEN, KIMBERLY CATHERINE | 1657 | §103 | Final Rejection | 29d overdue | Pending | Dec 21, 2023 |
| 18487680 | Selectively Frictionally Engaged Hole Cover | Clover Equipment, LLC | HARTMANN, GARY S | 3671 | §101DP | Final Rejection | — | Pending | Oct 16, 2023 |
| 18031109 | A DEVICE AND A METHOD FOR VAPORISING A VOLATILE MATERIAL | Inflowvent Ltd. | FULTON, MICHAEL TIMOTHY | 1747 | §103 | Final Rejection | 66d overdue | Pending | Apr 10, 2023 |
| 17596570 | Compositions, Kits, Methods and Uses for Preventing Microbial Growth | Collidion, Inc. | PETRITSCH, AMANDA MICHELLE | 1612 | §103 | Final Rejection | — | Pending | Dec 13, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial